GSK's eight-year carbon deal is a template without a price

GSK has committed to buy carbon credits for eight years from an Indian regenerative agriculture programme, under an agreement covering credits generated by Varaha across northern India and structured by Earthly, a nature-risk infrastructure firm. No price was disclosed, and on a deal whose value to the market lies in its architecture more than its tonnage, that missing number is the one rivals need.

The programme reaches more than 50,000 hectares and goes after two problems in the same fields: carbon held in agricultural soils, and the residue burning that farmers in Punjab and Haryana use to clear land quickly before the next planting season. Varaha's package runs to Direct Seeded Rice, reduced tillage and crop residues worked back into the soil, with participating farmers getting subsidised access to machinery and a share of the credit revenue; the obstacles are ordinary, because machinery and extra labour cost money and the alternatives take more time than a match does.

The eight-year term, more than the tonnage, is what turns this into a capital flow. A farmer weighing machinery he cannot finance against a burn that costs him nothing is not moved by a single season's credit payment; the subsidy is what changes the practice, and the revenue share is what keeps the subsidy survivable past year one. As this publication has argued, transition finance is migrating toward specific bottlenecks and project-level economics, and residue management across northern India has become one of them with a price attached.

GSK's own arithmetic explains the appetite for contracts of this shape: the company targets an 80% cut in emissions by 2030 against a 2020 baseline and intends to close the remaining 20% through nature protection and restoration. An eight-year offtake covering about 7% of GSK's forecast residual emissions implies, on that arithmetic, something on the order of a dozen comparable agreements to fill the gap — a portfolio spread across crops and states that may prove harder to organise than stubble in Punjab. Bundling emissions reductions with carbon dioxide removal in one contract helps, since buyers now answer for durability and for outcomes outside the carbon ledger. The co-benefits here run to fertiliser savings, soil and water retention, and the avoided burning behind the region's seasonal air pollution, and GSK has positioned human health as a key consideration in its nature investment strategy.

The next company to sign a contract like this one should copy the structure, not the announcement. If the following deal arrives with hectares under practice change, a named verification route and a price per tonne, project-level transition finance has a market. If it arrives with a logo and a hectare count, GSK's eight years of paper will read as the work of a buyer with an unusually specific taste in co-benefits.